semaglutide smpc ECO 2026 A, Trial design. Semaglutide was

Treatment typically begins with a low dose and is gradually increased at weekly or biweekly intervals

10.1007/s001250051551 130 HellermannG

[1] [2] Common adverse effects that women should anticipate include: Gastrointestinal symptoms (nausea, vomiting, diarrhoea, constipation) affecting up to 40% of users, typically most pronounced during dose escalation [1] [2] Injection site reactions such as redness or itching Headache and dizziness Fatigue , which might be particularly relevant for women already experiencing tiredness from fibroid-related anaemia Serious but rare risks include pancreatitis (inflammation of the pancreas), gallbladder disease, and hypoglycaemia, particularly in those taking other glucose-lowering medications

As discussed in Rabbani et al